SUNNYVALE, Calif. , Jan. 17, 2019 /PRNewswire/ -- According to the American Cancer Society , prostate cancer is the most common cancer in American men other than skin cancer. Accuray Incorporated (NASDAQ: ARAY) and The Urology Group (TUG) are partnering to recognize TUG's commitment to improving
System is Designed to Improve Treatment Results, Minimize Treatment Impact on Patients' Quality of Life SUNNYVALE, Calif. , Dec. 12, 2019 /PRNewswire/ -- Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact ® System , the next-generation
Availability of Industry-Leading Radiosurgery System at Japan’s Foremost Cancer Center Extends Accuray’s Market Share in Japan SUNNYVALE, Calif. , Feb. 27, 2012 /PRNewswire/ Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced installation of the CyberKnife®
SUNNYVALE, Calif., June 9, 2011 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: TOMO) by Accuray.
SUNNYVALE, Calif. , July 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System.
10-Year Anniversary of First Total Marrow Irradiation Delivery with the TomoTherapy® System Illustrates Growing Impact of Groundbreaking Approach SUNNYVALE, Calif. , June 9, 2015 /PRNewswire/ -- This month marks the 10-year anniversary of the first successful total marrow irradiation (TMI) using
- Accuray Precision™ Treatment Planning System and CyberKnife System Software Upgrade Enhances Efficiency and Ease-of-Use - Leading Radiation Oncology Providers at Institut Gustave Roussy, Lynn Cancer Institute, Multicare Hospital, Queen Elizabeth Hospital Birmingham, University Clinic for
SUNNYVALE, Calif. , Feb. 16, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from the randomized, multicenter trial PACE-A (PACE - Prostate Advances in Comparative Evidence) indicates that stereotactic body radiation therapy (SBRT), in comparison to surgery,
Expands Patient Access to the Benefits of Whole Body Radiosurgery SUNNYVALE, Calif ., June 19 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the Turkish Ministry of Health has purchased two CyberKnife(R) Robotic
UCLA Researchers Evaluate Long-term Outcomes of More than 1,000 Patients from Multiple Institutions SUNNYVALE, Calif. , Nov. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife®
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
